Servicios Personalizados
Revista
Articulo
Indicadores
- Citado por SciELO
- Accesos
Links relacionados
- Citado por Google
- Similares en SciELO
- Similares en Google
Compartir
Acta Neurológica Colombiana
versión impresa ISSN 0120-8748versión On-line ISSN 2422-4022
Resumen
PRADILLA, Oscar Enrique et al. Recommendations on the use of the antiCGRP monoclonal antibodies for migraine prophylaxis on behalf of the Colombian Association of Neurology. Acta Neurol Colomb. [online]. 2022, vol.38, n.1, suppl.1, pp.1-22. Epub 14-Jun-2022. ISSN 0120-8748. https://doi.org/10.22379/24224022401.
INTRODUCTION:
The development of monoclonal antibodies (mAbs) against Calcitonin Gene Related Peptide (CGRP) has determined a new therapeutic era in migraine prophylaxis, demonstrating its effectiveness in patients with episodic migraine (EM) and chronic migraine (CM), obtaining a response in naive patients and in those who are refractory to multiple medications. A 50% decrease in migraine attacks per month during the first 3 months of use is the approximate outcome in 50% of patients receiving this therapy.
OBJECTIVE:
This consensus from the Colombian Association of Neurology (ACN) has the objective of serving as a guide for the rational use of antiCGRP mAbs in patients with EM and CM.
METHODS AND MATERIALS:
The headache committee through the application of the Delphi methodology and discussions in subsequent meetings, develops this consensus, supported in the published literature and expert recommendations.
RESULTS:
Fourteen answers from headache experts were received regarding the use of drugs for migraine prophylaxis, analyzing their applicability in frequent clinical situations.
DISCUSSION:
AntiCGRP mAbs have proved their effectiveness with adequate pathophysiological support, but with a high price in a highly prevalent disease, there is then a need to select the patient who best benefits from this therapy.
CONCLUSIONS:
AntiCGRP mAbs are recommended in patients with EM and CM that have previously failed to other prophylactic drugs.
Palabras clave : Botulinum toxins Type A; Chronic pain; Headache; Migraine disorders; Monoclonal antibodies; Prevention and control (MeSH).